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The PRECIS-2 tool: designing trials that are fit for purpose
Kirsty Loudon,1 Shaun Treweek,1 Frank Sullivan,2 Peter Donnan,3 Kevin E Thorpe,4  
Merrick Zwarenstein5 
PRECIS is a tool to help trialists make 
design decisions consistent with the 
intended purpose of their trial. This 
paper gives guidance on how to use an 
improved, validated version, PRECIS-2, 
which has been developed with the 
help of over 80 international trialists, 
clinicians, and policymakers. Keeping 
the original simple wheel format, 
PRECIS-2 has nine domains—eligibility 
criteria, recruitment, setting, 
organisation, flexibility (delivery), 
flexibility (adherence), follow-up, 
primary outcome, and primary 
analysis—scored from 1 (very 
explanatory) to 5 (very pragmatic) to 
facilitate domain discussion and 
consensus. It is hoped PRECIS-2 will be 
valuable in supporting the explicit 
matching of design decisions to how 
the trial results are intended to be used
Randomised trials are hard work. Like much that is 
hard, this toil is only worth it because of the prospect of 
a substantial reward. For many important stakeholders 
(patients or others who may benefit from an interven-
tion, funders of healthcare and of research, practi-
tioners who may deliver clinical care and often the 
researchers themselves) the anticipated reward for a 
trial is that the results can be used to directly support 
decisions on delivering an intervention that will 
improve health outcomes for patients and the public. 
Key to this reward is that the trial can indeed support 
end user decisions in the ways intended by the trial 
design team. That this is not always, or even mostly, the 
case was highlighted nearly 50 years ago, by Schwartz 
and Lellouch in their paper on pragmatic and explana-
tory attitudes to randomised controlled trials.1
Simply put, these authors describe two purposes for 
randomised trials. A pragmatic randomised trial is 
undertaken in the “real world” and with usual care and 
is intended to help support a decision on whether to 
deliver an intervention. An explanatory randomised 
trial is undertaken in an idealised setting, to give the 
initiative under evaluation its best chance to demon-
strate a beneficial effect.2-4 These two approaches repre-
sent different attitudes to decision making on the 
usefulness of interventions. Moreover, although we will 
refer to trials as having an explanatory or a pragmatic 
intention throughout this paper, we recognise that 
there is no simple threshold and that there are few 
purely explanatory or pragmatic trials; rather than 
dichotomy there is a continuum.
There is widespread concern that explanatory ran-
domised trials can be poor predictors of the real world 
effectiveness of the interventions they test.4-7  Schwartz 
and Lellouch suggested that trialists often wish to inform 
a real world decision, but, almost by default, tend to 
design trials that are more explanatory than they should 
be given the designers’ intention. The original PRECIS 
(PRagmatic Explanatory Continuum Indicator Summary) 
tool was developed in 2005–08 by 25 international trial-
ists and methodologists8 to help trialists work through 
their design decisions so that they might avoid designing 
a trial that did not match their own intentions for the 
trial. There is demand for such tools; PRECIS has been 
cited over 300 times since 2009, it is one of eight “useful 
papers” for trialists listed on the UK National Institute for 
Health Research Randomised Trials Methods website 
(www.nets.nihr.ac.uk/resources/trials-coordination), 
and many investigators have used PRECIS prospectively 
and retrospectively to consider trial design.9 While 
acknowledging the usefulness of PRECIS, these latter 
authors have identified weaknesses, including unclear 
face validity and inter-rater reliability, the lack of a scor-
ing system, redundancy in some PRECIS domains, and 
the need for more guidance on how to use the tool.
This paper describes a new version of PRECIS, PRE-
CIS-2, which aims to address these (and other) weak-
nesses while keeping the strengths of the original tool, 
especially its simple format. The paper also provides 
guidance on how to use the tool. As with the original 
2009 PRECIS tool, we intend PRECIS-2 to be used at the 
design stage of a trial in order to help trialists make the 
purpose of their trial explicit and to ensure that their 
design choices are concordant with their intended 
Summary pointS
PRECIS (2009) was a tool with 10 domains to design clinical trials on a continuum of 
explanatory attitude (ideal situation) to more pragmatic attitude (usual care)
Cited over 300 times by end of 2014, but weaknesses have been highlighted: no rating 
scale, problems with some domains, needing better guidance, and not validated
This paper presents PRECIS-2—a validated, improved version of the tool—together 
with guidance for how to use it
PRECIS-2 has nine domains including three new ones (recruitment, setting, and 
organisation), each scored on a 5-point Likert continuum (from 1=very explanatory 
“ideal conditions” to 5=very pragmatic “usual care conditions”) so that trialists, 
clinicians, and policymakers can more easily consider whether design decisions 
match their intended purpose
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 purpose. We believe that it may have a role in other sit-
uations such as critical appraisal and systematic review 
as well as funding, ethics, and publication decisions on 
randomised trials.
aim
To present the PRECIS-2 tool and provide guidance on 
how to use it.
methods
This work is part of a larger project concerned with 
ensuring that trials are designed so that their results are 
relevant to, and used by, patients, clinicians, and policy 
decision makers.9  This paper presents the PRECIS-2 tool 
and gives guidance on how to use it but does not pres-
ent in full the work that led to it, which will be pub-
lished separately (see Loudon et  al9 or contact the 
authors for more information). 
Briefly, we ran a two-round Delphi communication 
with contact authors who had cited PRECIS but who 
had neither been involved in the original development 
of PRECIS nor evaluated the utility of PRECIS. We dis-
cussed how to improve PRECIS, focusing on issues 
raised by PRECIS users9 and brainstorming with trial-
ists in Dundee. The Delphi results were the basis for a 
brainstorming meeting in Toronto involving some of 
the original developers of PRECIS plus some of those 
who had undertaken methodological work using PRE-
CIS, together with clinicians and policymakers. We 
then user-tested candidate PRECIS-2 models, with 19 
international trialists, on a one-to-one basis (in person 
or via Skype). PRECIS-2 was modified in response to 
user testing. 
The version of PRECIS-2 that finally emerged was 
used in validity and reliability testing by 19 raters. 
These 19 raters had responded to an invitation we sent 
to 33 individuals, identified from four sources: the 
 Delphi, user testing, the Toronto brainstorming meet-
ing, and through our personal networks of experienced 
trialists. From these groups, 19 accepted the invitation 
(six from the Delphi, two from user testing, three from 
the Toronto meeting, and eight from our networks). The 
raters were asked to score a varied sample of 15 trial pro-
tocols. These protocols were purposefully selected to 
range from highly pragmatic to highly explanatory, 
including both drug and non-drug trials. This testing 
gave support for the proposed version of PRECIS 2, 
which is the version discussed in this paper.
Focus of prECiS-2
The PRECIS-2 tool focuses on trial design choices which 
determine the applicability of a trial. Applicability (the 
ability for a trial result to be applied or used in a partic-
ular situation) is the outcome of these choices, which 
affect the ease with which the trial results can be 
applied to and by the usual community of users of the 
intervention in the settings in which the trial designers 
envisioned it being used. This may, of course, vary for 
different readers, and thus applicability has both 
“local” and more distant meanings. The aim of a highly 
pragmatic trial would be to maximise applicability of 
the intervention to usual care across a range of local 
and distant settings. The aim of a highly explanatory 
trial would be to maximise the intervention’s chance of 
demonstrating an effect through the expected mecha-
nism, with little attention paid to the issue of whether 
this outcome would be achieved under real world con-
ditions, neither locally nor in more distant settings. 
Applicability is a continuum, and various trial design 
choices can make a trial more, or less, applicable; in 
other words more or less pragmatic.
In general, pragmatic trials are focused on care in the 
most common settings and are less commonly focused 
on highly specialised care settings. However, we believe 
that, even in specialised settings, a trial can be more or 
less applicable depending on the degree to which it pro-
vides care with resources and clinicians standard in 
that setting, to patients who are typical of that setting. 
Note that pragmatism constitutes only a close matching 
between the care delivered in the setting in which the 
trial was conducted and the care delivered in the setting 
to which its results are applied. This close matching 
provides directly applicable information and thus helps 
decision makers choose whether to implement the 
intervention tested in the trial.
How to use prECiS-2
The tool has been developed to be used by a multidisci-
plinary team throughout the process of designing their 
trial. This team will usually include expertise in the par-
ticular intervention and health service setting in which 
the intervention will be used, should it be shown to be 
effective, as well as statistical expertise.
There are four steps to using PRECIS-2, which may be 
iterative if there remains a gap between the intended 
purpose of the trial and the initial design choices, 
which will be revealed as the developing design is 
viewed through the prism of the PRECIS-2 tool.
Step 1: What design approach are you taking?
The first step is to be clear about your intention or atti-
tude to the trial you are designing. Are you
What is new in PRECIS-2 compared with PRECIS
•	A scale for all domains which can be scored from 1 (very explanatory) to 5 (very 
pragmatic)
•	Eligibility criteria has been placed on the 12 o’clock spoke
•	Clockwise use of PRECIS-2 with logical ordering of adjacent domains
•	The participant eligibility criterion (which might formerly have been thought of as 
including issues of setting and issues of multicentre trials) has been separated into 
“Eligibility” and “Setting”
•	New domains of “Recruitment” and “Organization”,
•	Domain name changes:
– From “Practitioner adherence” to “Flexibility: delivery” 
– From “Participant compliance” to “Flexibility: adherence” 
– From “Follow up intensity” to “Follow up” 
– From “Outcome” to “Primary outcome”
•	Removal of the comparison intervention domains of “Practitioner expertise” and 
“Flexibility of the comparison intervention”
•	Domain name labels on the PRECIS-2 wheel now come with short explanations
•	 Improved guidance on how to use PRECIS-2
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•	 Aiming to take an explanatory approach to answer 
the question, “Can this intervention work under ideal 
conditions?”
•	 Aiming to take a pragmatic approach to answer the 
question, “Does this intervention work under usual 
conditions?”
Both approaches to trial design have their place, but 
trialists should be clear which they would prefer to 
emphasise for the trial they are designing. As men-
tioned previously, trialists have often emphasised the 
first approach by default rather than as a deliberate 
decision.1
Step 2: Consider your trial design choices for each 
of the PRECIS-2 domains
This step is explained in more detail for each domain 
later on. Imagining first the most pragmatic and the 
most explanatory design choice you could make for 
each domain may help you in deciding how you wish to 
implement that domain choice, and thus how prag-
matic or explanatory you want your actual decision on 
that domain to be.
Before discussing the domains further, we should 
clarify what is meant by “participant.” Participants 
include patients or other individual recipients of an 
intervention, or providers of the intervention, or both. 
This may include individual participants or one or 
more levels of clusters. For example, in a trial of a con-
tinuing education intervention, participants may be 
health professionals and trained instructors, and the 
trial may be randomised into clusters at the level of the 
instructor. In some cluster trials, if randomisation 
occurs at two levels (such as organisation and individ-
ual participants), scoring of the domains may need to 
be considered separately.
Step 3: Score 1 to 5 for the choices made in Step 2 
and mark on the PRECIS-2 wheel
If there is uncertainty over how explanatory or prag-
matic your proposed trial design element is for a partic-
ular domain, then we suggest the score for this domain 
should be left blank; this will highlight the uncertainty 
and encourage discussion. Domains which have greater 
scoring variation by raters probably require further dis-
cussion and reiteration of steps 1 to 4 to clarify the 
design of this domain so there is greater agreement.
Having considered your design choices in Step 2, 
position your choice for each domain on the PRECIS-2 
wheel to record how pragmatic or explanatory these 
choices are for each domain. Scoring each domain can 
be done using a 5-point Likert scale:
1. Very explanatory
2. Rather explanatory
3. Equally pragmatic and explanatory
4. Rather pragmatic
5. Very pragmatic.
A toolkit with guidance and practical help is available 
to download from www.precis-2.org. The appendix on 
this website provides four examples of comparative 
effectiveness trials with explanations of our scoring 
decisions for the PRECIS-2 domains: a cluster ran-
domised trial in rural India to improve maternal and 
newborn health,10  a pharmacological primary care trial 
in UK to control asthma,11  an international music ther-
apy trial to treat preschool children with autism,12  and 
an international surgical trial for coronary angiogra-
phy.13  None of these trials, as far as we are aware, was 
designed using the PRECIS tool, and they do not refer to 
the Schwartz and Lellouch paper,1 so this is a post facto 
assessment, but nevertheless gives the reader some 
idea of how each domain may vary from pragmatic to 
explanatory.
Step 4: Review the PRECIS-2 wheel
Review your set of nine domain design choices (Step 2) 
on the PRECIS-2 wheel (figure) to see whether they will 
produce a trial that will support the overall aim you 
identified for your trial in Step 1. Go back to Step 2 and 
modify your design choices if required.
the nine domains of prECiS-2
PRECIS-2 has nine domains, each of which is intended 
to help trialists think about the consequences of that 
design decision for applicability of the results of their 
trial. The PRECIS-2 tool is focused exclusively on the 
issue of applicability, and readers should use other 
tools to assess the internal validity or any other aspect 
of their design choices.
Each domain encourages trialists to think about their 
trial and the recipients in the usual care situation in 
which their results might be applied if the intervention 
proves beneficial. If trialists are aiming for high applica-
bility (that is, a pragmatic approach to design decisions), 
Eligibility
Who is selected to
participate in the trial?
Recruitment
How are participants
recruited into the
trial?
Primary analysis
To what extent
are all data
included?
Primary outcome
How relevant
is it to
participants?
Setting
Where is the
trial being
done?
Organisation
What expertise and
resources are needed
to deliver the
intervention?
Follow-up
How closely are
participants
followed-up?
Flexibility: adherence
What measures are in place
to make sure participants
adhere to the intervention?
Flexibility: delivery
How should the
intervention
be delivered?
1
2
3
4
5
The PRagmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) wheel.
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then we would expect the match between trial and 
usual care to be very good. If trialists are aiming to give 
the intervention its best shot at showing a benefit (that 
is, an explanatory approach), then the match between 
trial and usual care may not be close. The point of PRE-
CIS-2 is not to always to produce a predominantly prag-
matic design (close match between trial and usual care) 
but to make trialists think about the aim of their trial 
and decide whether the design is appropriate given the 
aim of their trial. 
In pragmatic trials the comparator is usual care. In 
explanatory trials it may not be. In PRECIS-2 the 
domains are based on the assumption that the trial is 
two armed, one of which is usual care with no changes. 
If usual care is not the comparator, or there are multiple 
intervention arms that are very different from each 
other, then the arms will need to be scored separately; 
there may be differences in Organisation and Flexibility 
(delivery) and Flexibility (adherence).
The nine PRECIS-2 domains are:
1. Eligibility—To what extent are the participants in the 
trial similar to those who would receive this interven-
tion if it was part of usual care?
2. Recruitment—How much extra effort is made to 
recruit participants over and above what would be 
used in the usual care setting to engage with patients?
3. Setting—How different are the settings of the trial 
from the usual care setting?
4. Organisation—How different are the resources, pro-
vider expertise, and the organisation of care delivery 
in the intervention arm of the trial from those avail-
able in usual care?
5. Flexibility (delivery)—How different is the flexibility 
in how the intervention is delivered and the flexibility 
anticipated in usual care?
6. Flexibility (adherence)—How different is the flexibil-
ity in how participants are monitored and encour-
aged to adhere to the intervention from the flexibility 
anticipated in usual care?
7. Follow-up—How different is the intensity of measure-
ment and follow-up of participants in the trial from 
the typical follow-up in usual care?
8. Primary outcome—To what extent is the trial’s pri-
mary outcome directly relevant to participants?
9. Primary analysis—To what extent are all data 
included in the analysis of the primary outcome?
the domains in detail
1. Eligibility criteria—Who is selected to participate 
in the trial?
A highly pragmatic approach to eligibility criteria 
would be to include in the trial anyone with the condi-
tion of interest who is likely to be a candidate for the 
intervention if it was being provided in usual care for 
this condition. So, if in usual care the intervention 
would likely be used for children, elderly people, peo-
ple with a range of comorbidities, and people with a 
probable diagnosis rather than, say, a laboratory con-
firmed diagnosis, then all of these groups should be in 
the trial too. If people aged over 80 or with multiple 
morbidities would not receive the intervention in usual 
care because we already know that this intervention 
does more harm than good in elderly or multi-morbid 
patients, then a pragmatic design choice would be to 
exclude them from the trial. A trial with eligibility 
design choices like this would score at or close to 5 on 
the PRECIS-2 scale.
As the level of similarity between the people in the 
trial and those in usual care decreases, then so would 
the PRECIS-2 score. Many things could reduce the score, 
but some examples include
•	 Excluding people not known or shown to be highly 
adherent to the intervention.
•	 Excluding people using tests or measures that are not 
used or available in usual care.
•	 Excluding people not expected to be highly respon-
sive to the intervention.
•	 Excluding people who would be likely to receive the 
intervention in usual care but inclusion in the trial is 
considered too difficult because of challenges unre-
lated to the delivery of the intervention. Children, 
people over the age of 65, and pregnant women are 
good examples of people commonly excluded 
because of anticipated difficulties of gaining ethical 
approval rather than whether they would be likely to 
receive an intervention in usual care.
•	 Excluding people whose adherence and follow-up 
may pose difficulties, whether because of social dis-
advantage, personal circumstances, or illness (such 
as homelessness, substance misuse, mental health 
problems, or poor motivation).
•	 Excluding people dependent on help for activities of 
daily living, unless they would usually not be eligible 
for intervention.
Trialists may make their trials less like usual care by 
having tight inclusion criteria and broad exclusion 
Eligibility criteria, example 1: Early treatment with 
prednisolone or acyclovir in Bell’s palsy*
•	 Inclusion criteria—Patients with confirmed diagnosis: 
≥16 years of age with unilateral facial nerve weakness 
of no identifiable cause who presented to primary 
care or an emergency department and could be 
referred to a collaborating otorhinolaryngologist <72 
hours after the onset of symptoms.
•	Exclusion criteria—Pregnancy, breast feeding, 
uncontrolled diabetes, peptic ulcer disease, 
suppurative otitis media, herpes zoster, multiple 
sclerosis, systematic infection, sarcoidosis and other 
rare conditions, and an inability to provide informed 
consent.
•	Extra test—Randomised controlled trial of Bell’s palsy 
treatment required senior otorhinolaryngologist in 
hospitals to confirm a patient’s eligibility to 
participate. Bell’s palsy is usually diagnosed by a 
general practitioner in primary care.
•	Suggested PRECIS score—2, rather explanatory.
*Sullivan FM, Swan IR, Donnan PT, et al. A randomised 
controlled trial of the use of aciclovir and/or prednisolone 
for the early treatment of Bell’s palsy: the BELLS study. 
Health Technol Assess 2009;13:iii-iv, ix-xi, 1-130.
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 criteria. For trialists taking an explanatory approach 
this is often appropriate, but this is unlikely to be the 
case for trialists aiming to design a trial that is directly 
applicable in a particular usual care setting, let alone 
one intended to have wide generalisability across mul-
tiple care settings. Under certain circumstances, a trial 
design may be pragmatic (and the results highly appli-
cable to the usual care of the participants under study) 
even with narrow eligibility criteria if the particular 
narrow criteria are similar to those routinely used for 
those participants in their usual care setting. Some 
rare disease trials may fall into this category. Trials in 
myotonic dystrophy type 1, for example, may require a 
genetic confirmation of the diagnosis, but since most 
patients with myotonic dystrophy type 1 receive their 
diagnosis through genetic confirmation this inclusion 
criterion simply reflects what is usual practice. Finally, 
exclusion criteria for known safety issues would not 
generally reduce the PRECIS-2 score since such indi-
viduals would not be expected to get the intervention 
in usual care.
2. Recruitment—How are participants recruited into 
the trial?
This domain has been included to encourage trialists to 
consider how and where they will recruit people to their 
trial. (For clarity, we have described only trials involv-
ing patients, but, as stated above, participants could be 
groups of practitioners or health system where the goal 
is to improve some aspect of care at the intervention 
unit of clinics, wards, hospitals, or geographic area.)
The most extreme pragmatic approach to recruitment 
would be to do this in usual care so that only the people 
who attend a clinic with the condition of interest are 
recruited after they present on their own behalf without 
any overt recruitment effort. A highly pragmatic 
approach to trial design would also recruit from more 
than one clinic as an explicit way of increasing applica-
bility of the trial results. Recruiting through usual 
appointments at a diverse range of clinics is likely to 
score at or close to 5 on the PRECIS-2 scale.
If the above is not feasible, at least as the sole recruit-
ment route, trialists will need to add other recruitment 
strategies. If extra resources will be required to recruit 
people to the trial, trialists need to consider if this 
affects applicability, especially if participants are 
recruited from settings other than the one in which the 
results are likely to be applied. For example, recruiting 
in secondary care for an intervention that will mainly 
be used in primary care will ensure that the recruited 
patients are different in severity and treatment than the 
patients with this same condition in primary care; and 
so this will make the trial more explanatory and reduce 
the PRECIS 2 score. Additional recruitment approaches 
that could potentially reduce the PRECIS-2 score 
include
•	 Searching medical record systems for eligible partic-
ipants and then mailing invitation letters. Depending 
on local resources, such as electronic medical records 
and comprehensive local disease registers, this 
approach may be easily achievable in usual care and 
so would not reduce the PRECIS-2 score.
•	 Media advertising campaigns such as television 
and radio advertisements, newspaper advertise-
ments, flyers, websites, press releases, letters to the 
editor, interviews with the chief investigator on 
television or radio. The issue to consider here is 
whether these campaigns are being used simply to 
speed up recruitment, or because they are the only 
way to reach a dispersed population. In the latter 
case, if such campaigns would not be available in 
usual care then this trial recruitment route is more 
explanatory.
•	 Incentives such as cash payment, vouchers, travel 
costs, or childcare. Some of these incentives may be 
better considered as part of the intervention (for 
example, a lifestyle change intervention aimed at 
new mothers may only be effective because childcare 
was also provided and women could therefore attend 
sessions).
Eligibility criteria, example 2: Practical approach to 
lung health in South Africa*
•	 Inclusion criteria—All patients aged ≥15 with 
suspected asthma were included in the study, based 
on a crude clinical diagnosis of asthma, as the 
standard respiratory testing machinery was not 
available in this rural setting in South Africa.
•	Suggested PRECIS score—5, very pragmatic.
*Fairall LR, Zwarenstein M, Bateman ED, et al. Effect of 
educational outreach to nurses on tuberculosis case 
detection and primary care of respiratory illness: pragmatic 
cluster randomised controlled trial. BMJ 2005;331:750-4.
Recruitment, example: Leukotriene antagonists for 
asthma treatment*
•	 Initially extra resources were used to recruit patients 
at 53 primary care practices. Patients were recruited 
via a postal questionnaire to identify symptoms and 
trial eligibility, not just to invite to participate. This 
would push the recruitment path of this domain 
towards the explanatory end. By using this method of 
recruitment, which requires administration not 
normally present in primary care, it is possible that 
responders may be healthier than those at the clinic 
being invited to the trial and also more highly 
motivated and compliant as they have come through 
a different route than those invited during a clinic 
attendance.
•	 In this trial, recruitment was inadequate using a 
postal questionnaire, so participants were then 
recruited through clinic attendances changing the 
recruitment towards a more pragmatic trial design, 
creating results which are more applicable to users of 
the results in a primary care setting.
•	Suggested PRECIS score—2, rather explanatory; but, 
as trial continued, a PRECIS score of 3 (equally 
pragmatic and explanatory) since trial now more a 
mix of recruitment methods, some of which are 
feasible in usual care.
*Price D, Musgrave SD, Shepstone L, et al. Leukotriene 
antagonists as first-line or add-on asthma-controller therapy. 
N Engl J Med 2011;364:1695-707.
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3. Setting—Where is the trial being done?
This domain has been included to encourage trialists to 
explicitly consider the match between the setting of 
their trial and the setting where their results are likely to 
be applied. While there are no accepted guidelines for 
how to assess the impact of setting on applicability,5 
there are several characteristics of the setting that will 
almost always need to be considered, including geogra-
phy, healthcare system, country, and the socioeco-
nomic and ethnic mix of the population.4 14 15 All of 
these might affect the applicability of results from a 
particular trial.
The most extremely pragmatic approach to setting 
would be to do the trial in an identical setting to which 
you intend the results to be applied. Such a trial is likely 
to score at or close to 5 on PRECIS-2.
Even settings that seem rather restrictive could still 
be a highly pragmatic design choice if this setting is the 
usual care setting where patients are treated for the par-
ticular health condition. For example, if a trial was car-
ried out in the most specialist intensive care units in the 
country and the intention of the trial was to support 
decision making in these highly specialised units, then 
the design choice with regard to setting is still prag-
matic. Conversely, if the trial results were intended to be 
useful for all intensive care units, but the trial included 
only highly specialised units, then the trial is now tak-
ing a more explanatory approach to the choice of set-
ting that goes against the intention of the trial.
Determining how pragmatic or explanatory a setting 
is can be problematic when there is a proposed change 
in the setting for care delivery. For instance, if a trial is 
carried out in secondary care and the intention is that, 
if the change in setting is successful, all future care will 
be delivered in this setting, then this new setting will be 
become the usual care setting. In this case the setting 
domain in the trial would be explanatory compared 
with current usual care, but trialists can note that the 
difference is an explicit feature of the intervention.
Approaches to setting that are likely to reduce the 
PRECIS-2 score include
•	 Selecting participating centres from among only spe-
cialist or academic centres when the trial is intended 
to be applicable to all types of practice or clinic treat-
ing the condition of interest.
•	 Running the trial in a single centre. It is rare that a 
trial is done with the intention that its results should 
apply to only that single centre. Including several 
centres makes it easier to claim that the trial setting 
matches that to which the results will be applied.
Trialists working on trials that cross jurisdictions (such 
as international trials) need to use their judgment with 
regard to the impact these different settings have on the 
overall trial applicability. If the trial is delivered in the 
same setting as usual care in each jurisdiction then the 
trial is likely to score as pragmatic on PRECIS-2, even if 
the settings are different in each jurisdiction. In this 
case, the trial randomisation would be stratified by 
jurisdiction.
4. Organisation—What expertise and resources are 
needed to deliver the intervention?
This domain has been included to encourage trialists to 
consider the match between how care is organised and 
delivered in the trial and how the intervention would be 
made available to patients in usual care. As there have 
been acknowledged difficulties in implementing results 
post-trial (even in settings where the trial was con-
ducted16), we wanted trialists to consider organising the 
delivery of their trial intervention with an awareness of 
how easy it would be to implement the intervention 
post-trial .
A highly pragmatic design would aim to slot the inter-
vention into the usual organisation of care for the condi-
tion of interest, making use of no more than the existing 
healthcare staff and resources in that setting. A design 
like this is likely to score at or close to 5 on PRECIS-2.
Sometimes a change to how care is organised is itself 
the intervention being evaluated (see, for example, 
Zwarenstein et al’s trial of directly observed treatment 
(DOTS) versus self-supervised treatment for tuberculo-
sis17), and the difference between the trial and usual 
care is clear. In this case the organisation domain would 
be explanatory compared with current usual care, but 
trialists can note that the difference is an explicit fea-
ture of the intervention.
The PRECIS-2 organisation score will be reduced to 
the degree trialists make changes in how care is deliv-
ered compared with the usual recipients and care deliv-
ery. For example, the trial team may, in the intervention 
arm, provide additional training to staff or provide 
additional staff so that the intervention can be deliv-
ered. Patients who would normally be seen in primary 
Setting, example 2: Ibuprofen, paracetamol, and 
steam for patients with respiratory tract infections in 
primary care*
•	 Identical setting to usual care setting: primary care, 
where patients usually go for advice and treatment of 
the common cold in the UK.
•	Multi-centre: 25 practices in UK.
•	Suggested PRECIS score—5, very pragmatic
*Little P, Moore M, Kelly J, et al. Ibuprofen, paracetamol, and 
steam for patients with respiratory tract infections in primary 
care: pragmatic randomised factorial trial. BMJ 
2013;347:f6041.
Setting, example 1: Manual physical therapy versus 
corticosteroid injection to treat shoulder 
impingement*
•	Single centre and specialised centre (Madigan Army 
Medical Center, USA), unlikely to be the usual setting 
for most individuals receiving physiotherapy for 
shoulder impingement.
•	Suggested PRECIS score—2, rather explanatory, 
dependent on how different raters think the 
treatment centre is similar from usual setting in the 
country they live in.
*Rhon DI, Boyles RE, Cleland JA, et al. A manual physical 
therapy approach versus subacromial corticosteroid injection 
for treatment of shoulder impingement syndrome: a protocol 
for a randomised clinical trial. BMJ Open 2011;1:e000137.
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care may be seen by specialists in secondary care 
instead, or they may receive additional expensive diag-
nostic procedures unavailable in usual care. The suc-
cess or otherwise of the trial then depends on resources 
unavailable in usual care, reducing applicability. If 
these additional resources are essential to the effective-
ness of the intervention they should be considered to be 
part of the intervention and be specified in the part of 
the protocol describing the intervention. In that case 
these resources should not be counted when this ele-
ment of the trial is judged.
Organisational approaches that are likely to reduce 
the PRECIS-2 score include the following (but only 
when they are not incorporated and described as neces-
sary elements of the intervention):
•	 Increasing the number of healthcare or other profes-
sionals available to deliver the intervention over and 
above the levels available in usual care.
•	 Providing significant levels of additional training to 
increase the expertise of healthcare professionals.
•	 Requiring healthcare professionals to have some 
minimum level of experience, defined by length of 
time, in working with the intervention that is greater 
than would be the case in usual care.
•	 Requiring healthcare professionals to have a spe-
cialty certification that would not be considered 
essential to deliver the intervention in usual care.
•	 Increasing the resources (such as facilities, diag-
nostic equipment, consumables) available to 
deliver the intervention, measure outcomes, or do 
follow-up over and above what would be available 
in usual care.
5. Flexibility (delivery)—How should the intervention 
be delivered?
In PRECIS-2, trialists wishing to conduct more pragmatic 
trials are encouraged to think about how the interven-
tion will be implemented post-trial in the setting where 
the results are expected to be applied. The most prag-
matic design approach to delivery flexibility would leave 
the details of how to implement the intervention up to 
providers, in other words, what happens in usual care. 
Thus, the methodology of how to deliver an intervention 
is not rigidly prescriptive in the protocol. For example, 
the details of how to perform a surgical procedure could 
be left entirely to the surgeon, or how to deliver an edu-
cational programme is left to the discretion of the educa-
tor. Additionally, a pragmatic approach would not 
dictate which other interventions were permitted, or 
how to deliver them, which again is the situation in 
usual practice. This sort of delivery flexibility would 
score at or close to 5 on PRECIS-2. Flexibility (delivery) 
applies to all intervention arms and the comparator 
(control) arm if usual care is not the comparator, and if 
necessary each of these arms will need to be scored sep-
arately. If usual care is the intended comparator but any 
elements relating to delivery are changed it ceases to be 
usual care and needs to be scored.
As delivery flexibility is reduced, the trial moves 
towards a more explanatory approach in this domain. 
Approaches to delivery flexibility that are likely to 
reduce the PRECIS-2 score include
•	 A highly specified, protocol driven intervention. For 
example, specific direction is given for how to the 
administer the intervention (such as dose, dosing 
schedule, surgical procedures, educational material, 
and delivery)
•	 Having measures in place to monitor the compliance 
of those delivering the intervention (such as doctors) 
Organisation, example 1: Establishment of Acute 
Respiratory Distress Syndrome (ARDS) Network in 
1994*
•	Multicentre clinical trials of ARDS treatments, but 
there was difficulty translating results from a trial 
involving low tidal volume (Vt) into usual clinical 
practice
•	Ten academic centres with 75 intensive care units
•	Extra staff, and very labour intensive
•	Used additional equipment beyond usual care, none 
of which was planned for at the trial design stage
•	Suggested PRECIS score—1, very explanatory
*Ventilation with lower tidal volumes as compared with 
traditional tidal volumes for acute lung injury and the acute 
respiratory distress syndrome. The Acute Respiratory Distress 
Syndrome Network. N Engl J Med 2000;342:1301-8.
Organisation, example 2: Early lens extraction and 
intraocular lens implantation to treat glaucoma*
•	 Identical organisation to usual care, usual clinic
•	Same number of staff
•	Usual experience—fully qualified ophthalmologists 
who have completed general and specialist training 
(in ophthalmology and glaucoma, respectively) and 
able to perform lens extraction procedures
•	No additional training
•	No additional resources
•	Suggested PRECIS score—5, very pragmatic
*Azuara-Blanco A, Burr JM, Cochran C, et al. The 
effectiveness of early lens extraction with intraocular lens 
implantation for the treatment of primary angle-closure 
glaucoma (EAGLE): study protocol for a randomized 
controlled trial. Trials 2011;12:133.
Flexibility (delivery), example 1: Cognitive 
behavioural therapy (CBT) for depression*
•	Measures in place to monitor and improve 
compliance: In this trial therapy was delivered by 
selected experts who received regular training and 
supervision (but were independently assessed as 
representative of NHS staff). There was also 
independent assessment to confirm minimum 
standard of delivery of CBT but no measures in place 
to improve compliance as this was self regulated by 
therapists.
•	No specific protocol for timing or co-interventions
•	Suggested PRECIS score—5, very pragmatic
*Wiles N, Thomas L, Abel A, et al. Cognitive behavioural 
therapy as an adjunct to pharmacotherapy for primary care 
based patients with treatment resistant depression: results 
of the CoBalT randomised controlled trial. Lancet 
2013;381:375-84.
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with the protocol and measures (up to and including 
exclusion) to address poor compliance.
•	 The timing of intervention delivery is tightly defined 
and designed to maximise the intervention effect.
•	 Providers undertake additional interventions that 
would not occur in usual care
•	 Restrictions are placed on the number and types of 
co-interventions, particularly if excluded co-inter-
ventions would dilute any intervention effect
•	 There is specific direction for applying permitted 
co-interventions
•	 There are specific directions for managing complica-
tions or side effects of the intervention.
6. Flexibility (adherence)—What measures are in 
place to ensure participants adhere to the 
intervention?
It is important that trialists focused on applicability con-
sider how probable it is that there will be uptake of the 
intervention being tested and how recipients will engage 
with it in the setting in which it will be later applied. 
A highly pragmatic design approach would allow for full 
flexibility in how end user recipients engage with the 
intervention. In usual care, health professionals encour-
age patients to take medication or follow therapy as best 
they can, and such encouragement would not count 
against a pragmatic design; if it also happens in usual 
care, allowing it in the trial is a pragmatic design deci-
sion. A trial with no special measures to enforce engage-
ment or compliance would score at or close to 5 on 
PRECIS-2. On the other hand, a trial protocol that lays 
out methods to monitor and ensure patient compliance 
would score at or close to 1 on PRECIS-2. Flexibility 
(adherence) applies to all intervention arms and the 
comparator (control) arm if usual care if not the compar-
ator, and if necessary each of these arms will need to be 
scored separately. If usual care is the intended compar-
ator but any elements relating to adherence are changed 
it ceases to be usual care and needs to be scored.
It is possible that improving recipients’ ability to take 
medication or follow therapy is the intervention under 
evaluation, a situation similar to that already described for 
the Setting and Organisation domains. In this case, the 
Flexibility (adherence) domain would be explanatory 
compared with current usual care, but trialists can note 
that the difference is an explicit feature of the intervention.
As flexibility for recipients is reduced, the trial moves 
towards a more explanatory approach on this domain. 
Approaches to recipient flexibility that are likely to 
reduce the PRECIS-2 score include
•	 Having a trial pre-screening stage where patients are 
evaluated for adherence with the intervention (such 
as dose, dosing schedule, attendance at therapy ses-
sions). Patients judged to not be adherent are 
excluded.
•	 Withdrawing patients from the trial if their adherence 
with the intervention drops below some specified 
level. For example, a trial might withdraw patients if 
they failed to attend two consecutive sessions of cog-
nitive behavioural therapy or failed to take more than 
90% of their medication.
•	 Having measures in place to monitor patient adher-
ence with the protocol and measures (up to and 
including withdrawal) to address poor adherence. 
Measures to increase patient adherence should this 
fall below some specified level could, for example, 
include scheduling an extra discussion with a 
research nurse about why following the trial instruc-
tions is important.
In some trials—such as surgical trials where patients 
are being operated on or intensive care unit trials where 
patients are being given intravenous drugs—this 
domain is not applicable as there is no adherence issue 
after consent has been given, so we suggest that the 
PRECIS-2 score should be left blank.
7. Follow-up—How closely are participants 
followed up?
This domain encourages trialists to think about fol-
low-up with regard to the setting where the results will be 
applied. The most pragmatic position with regard to fol-
low-up would be to have no more follow-up of recipients 
than would be the case in usual care. Indeed, the most 
extreme position is to have no follow-up contact at all 
with recipients and to obtain outcome data by other 
means (such as electronic medical records or other usual 
data to measure mortality or hospital admissions). Trials 
that have no more follow-up than is normal in usual care 
and have minimal additional data collection (or use data 
obtained from administrative or clinical record systems 
without direct contact with the participant) would be 
likely to score at or close to 5 on PRECIS-2.
Flexibility (delivery), example 2: Elective caesarean 
section syntocinon infusion trial*
•	Protocol driven—Much detail given, with protocol 
violations recorded in self reported case form. 
Investigators accept this may occur due to clinical 
needs (such as anaesthesia).
•	Co-interventions—Specific direction
•	Complications—Specific directions for managing 
complications or side effects
•	 Improving adherence—No measures in place
•	Suggested PRECIS score—2, rather explanatory
*Murphy DJ, Carey M, Montgomery AA, et al. Study protocol. 
ECSSIT—Elective Caesarean Section Syntocinon Infusion 
Trial. A multi-centre randomised controlled trial of oxytocin 
(Syntocinon) 5 IU bolus and placebo infusion versus oxytocin 
5 IU bolus and 40 IU infusion for the control of blood loss at 
elective caesarean section. BMC Pregnancy Childbirth 
2009;9:36.
Flexibility (adherence), example: Music therapy to 
support communication in autistic children*
•	The sessions were all individual based on interaction 
with child and allowed for range of responses to the 
intervention
•	Suggested PRECIS score—5, very pragmatic
*Geretsegger M, Holck U, Gold C. Randomised controlled 
trial of improvisational music therapy’s effectiveness for 
children with autism spectrum disorders (TIME-A): study 
protocol. BMC Pediatr 2012;12:2.
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As follow-up becomes more intense, the trial 
becomes more explanatory and the PRECIS-2 score will 
decrease. Follow-up approaches that are likely to 
reduce the PRECIS-2 score include
•	 Follow-up visits that are more frequent than would 
typically occur under usual care.
•	 Unscheduled follow-up visits are triggered by a pri-
mary outcome event.
•	 Unscheduled follow-up visits are triggered by an 
intervening event that is likely to lead to the primary 
outcome event.
•	 Patients are contacted if they fail to keep trial 
appointments. This would not reduce the PRECIS-2 
score if this was also done in usual care.
•	 More extensive data are collected, particularly interven-
tion related data, than would be typical outside the trial.
•	 Visits are longer than usual care and involve addi-
tional or different staff.
Often the required trial outcomes may be obtained only 
through contact with the recipients. Even in the “no fol-
low-up” approach, assessment of outcomes may be 
achieved with a single follow-up at the end of the study. 
The end of study would need to be defined so that there 
is sufficient time for the desired study outcomes (see 
Primary outcome domain below) to be observed. When 
the follow-up is done in this way, it is unlikely to have 
an impact on engagement or response to the treatment, 
and so such a follow-up approach would be viewed as 
pragmatic and rated at or close to 5.
It is often the case that explanatory trials are inter-
ested in the effect of an intervention only during a brief 
intervention period or shortly after. On the other hand, 
trials taking a pragmatic approach to design may follow 
recipients well beyond the intervention period. This 
longer period of follow-up may require more contacts 
than would be the case in usual care, but this need not 
be inconsistent with a pragmatic approach if it does not 
result in care management that differs from the usual 
conditions. It is, however, important to consider the 
burden of follow-up for participants.
8. Primary outcome—How relevant is it to 
participants?
The choice of primary outcome is a crucial trial design 
decision, and a pragmatic approach would be to select an 
outcome that is of obvious importance from the patient’s 
perspective. Post-trial, an outcome selected using a prag-
matic approach would also be relevant to commissioners 
of care, the people who decide whether to implement the 
intervention on the basis of its results. For example, an 
intervention that aims to reduce falls in elderly people 
living independently in the community should have as its 
primary outcome the number of falls in the elderly living 
independently in the community. This outcome has 
meaning to patients, their relatives and friends, health-
care professionals, and policymakers. Measures of, say, 
bone density, muscle strength, or functional ability are 
distant from the key question of whether the intervention 
prevents elderly people falling in their own homes. Trials 
that choose outcomes of obvious importance to patients, 
and measure them in a way that is the same or similar to 
the way they are measured in usual care would be likely 
to score at or close to 5 on PRECIS-2.
As the primary outcome becomes less recognisably 
important to patients, or is assessed on criteria seldom 
used in usual care, the trial becomes more explanatory 
and the PRECIS-2 score will decrease. Approaches to the 
primary outcomes that are likely to reduce the PRECIS-2 
score include
•	 Choosing a surrogate outcome (such as blood test) 
that the intervention is expected to have a direct 
Follow-up, example 2: Self management course for 
chronic musculoskeletal pain*
•	Participants followed up two times over a year (at 6 
and 12 months)—not intense. This is quite close to 
usual care for pain related disability.
•	Follow-up for the primary outcome requires self 
completion of a postal validated questionnaire 
chronic pain grade, which contains three questions 
to determine the primary outcome “pain related 
disability” (and secondary outcome “pain 
intensity”).
•	No additional follow up visits—All additional data 
collection for secondary outcomes use six additional 
short postal questionnaires sent at 6 and 12 months: 
EQ-5D (health utility), Pain Self-Efficacy 
Questionnaire, Hospital Anxiety and Depression 
Scale (mood), Chronic Pain Acceptance 
Questionnaire (coping), Health Education Impact 
Questionnaire (social integration subscale), Census 
global health question (general health).
•	Additional data from GP electronic records
•	Suggested PRECIS score—4, rather pragmatic
*Carnes D, Taylor SJ, Homer K, et al. Effectiveness and 
cost-effectiveness of a novel, group self-management course 
for adults with chronic musculoskeletal pain: study protocol 
for a multicentre, randomised controlled trial (COPERS). BMJ 
Open 2013;3:e002492.
Follow-up, example 1: Perioperative β blockade for 
patients undergoing infrarenal vascular surgery*
•	Clinical follow-up until patient left hospital 
(discharge or death) or until 30 days after surgery, 
whichever was the longer, so more than usual care.
•	Monitoring intensity involved more extensive data 
collection than usual:
Pre-operation—three-lead electrocardiogram (ECG) 
Holter monitor (Flashcard with 2×48 hour 
recording) set up on each patient and maintained 
for 72 hours.
Troponin values at 1, 3, and 7 days after surgery 
(more usual for only 1 and 3 days after surgery)
ECG after randomisation and at 7 and 30 days after 
surgery.
•	Unscheduled follow-up visits triggered by primary 
outcome: a cardiovascular event (such as angina, 
myocardial infarction, stroke)
•	Suggested PRECIS score—1, very explanatory
*Brady AR, Gibbs JSR, Greenhalgh RM, et al. Perioperative 
beta-blockade (POBBLE) for patients undergoing infrarenal 
vascular surgery: results of a randomized double-blind 
controlled trial. J Vasc Surg 2005;41:602-9.
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effect on, or the use of safety climate surveys rather 
than medical error events or near miss events.
•	 Using a composite primary outcome in which some of 
the elements are less important to patients or partici-
pants than others (such as incidence of death, stroke, 
myocardial infarction, or renal dysfunction at 30 days).
•	 Having central adjudication of the outcome or using 
an assessment that needs special training or tests not 
normally used in usual care.
•	 Choosing an outcome that is important but mainly to 
providers, typically because it is a physiological out-
come considered useful in treatment planning and 
monitoring.
•	 Measuring an outcome that is important but at a time 
that is earlier than would be normal in usual care. For 
example, stroke could be a primary outcome in trials 
making explanatory or pragmatic design choices. 
However, time horizons may vary from short term 
after a one-time intervention (more explanatory) to 
long term (more pragmatic).
9. Primary analysis—To what extent are all data 
included?
Most trials are a superiority design so the most prag-
matic approach with regard to the analysis would be to 
make no special allowance in the analysis for non-ad-
herence, practice variability, etc. In other words, the 
pragmatic approach to the analysis would typically be 
an intention-to-treat analysis using all available data. 
This sort of analysis would score at or close to 5 on PRE-
CIS-2. (Non-inferiority and equivalence trials are usu-
ally contrary to intention-to-treat analysis.)
The intention-to-treat analysis has recently also 
become the norm for superiority trials taking a more 
explanatory design approach, especially when regula-
tory approval for an intervention is being sought. The 
most explanatory approach would be to use the “as 
treated analysis” as the primary analysis, in which only 
those patients who actually received (or did not receive) 
the intervention would be analysed in the intervention 
and control groups respectively, irrespective of their ini-
tial randomised group allocation.
Other causes of missing data may be important but may 
not affect how pragmatic or explanatory a trial is. System-
atic exclusion of data from participants because, say, they 
were poorly adherent would make a trial more explana-
tory. Using all data but doing nothing to try and fill gaps 
caused by missing data would not in itself make trial 
more pragmatic or explanatory; missing data, especially 
if there is a lot of it, makes any conclusions more uncer-
tain regardless of the design approach taken. As Vickers 
and Altman state, “analysis of missing data teaches us 
the importance of avoiding missing data in the first place: 
an informed guess, even using a technique as sophisti-
cated as multiple imputation, is still a guess.”18
Approaches to the primary analysis that are likely to 
reduce the PRECIS-2 score include
•	 Excluding non-compliant recipients (per protocol 
analysis)
•	 Analyse recipients to treatment received instead of 
treatment randomised (as treated analysis)
•	 Excluding data from non-adherent providers
•	 Excluding data from trial sites or providers who 
recruit below expected volume.
For some trials taking an explanatory approach (dose 
finding trials are an example), it may be appropriate to 
have primary analysis restricted in the ways mentioned; 
otherwise such restricted analyses of the primary out-
come could be pre-planned as secondary analyses of 
the primary outcome.
Conclusion
PRECIS-2 has been developed through extensive interna-
tional consultation with trialists, and we believe it will 
help trialists (new and experienced) ensure that they 
Primary outcome, example: Early treatment with 
prednisolone or acyclovir in Bell’s palsy*
•	Primary outcome—Recovery of facial function as 
rated on the House-Brackmann scale.
•	Test not routinely used in primary care and requires 
training. It is, however, an easy clinical test widely 
used in secondary care for grading recovery from 
facial nerve paralysis caused by damage to lower 
motor neurons.
•	Central adjudication—Photographs taken of patients 
were assessed and graded independently by a panel 
of three experts (not general practitioners, who 
usually assess).
•	Suggested PRECIS score—1, very explanatory
*Sullivan FM, Swan IR, Donnan PT, et al. A randomised 
controlled trial of the use of aciclovir and/or prednisolone 
for the early treatment of Bell’s palsy: the BELLS study. 
Health Technol Assess 2009;13:iii-iv, ix-xi, 1-130.
Primary analysis, example 1—Self management 
course for chronic musculoskeletal pain*
•	 Intention-to-treat principle was applied with multiple 
imputation of data
•	Suggested PRECIS score—5, very pragmatic
*Carnes D, Taylor SJ, Homer K, et al. Effectiveness and 
cost-effectiveness of a novel, group self-management course 
for adults with chronic musculoskeletal pain: study protocol 
for a multicentre, randomised controlled trial (COPERS). BMJ 
Open 2013;3:e002492.
Primary analysis, example 2—Effects of rosuvastatin 
versus atorvastatin on LDL and HDL cholesterol in 
patients with type IIa or IIb hypercholesterolemia*
•	Dietary lead in to screen and exclude non-compliers, 
then post-randomisation excluded non-compliers 
who did not take medication, so “per protocol 
analysis.” The trial did, however, include those who 
violated protocol, deviated from protocol, or 
withdrew (mainly due to adverse events)
•	Suggested PRECIS score—2, rather explanatory
*Davidson M, Ma P, Stein EA, et al. Comparison of effects on 
low-density lipoprotein cholesterol and high-density 
lipoprotein cholesterol with rosuvastatin versus atorvastatin 
in patients with type IIa or IIb hypercholesterolemia. Am J 
Cardiol 2002;89:268-75.
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match their design decisions to the needs of those they 
intend to use the results of the trial. It makes trial teams 
explicitly aware of the range of opinions within the team 
and facilitates discussion and eventual consensus. The 
tool aims to assist in obtaining consistency in decision 
making, meaning decisions made on each domain of 
PRECIS-2 should broadly be in keeping with each other. It 
does not remove the need for judgment because there is 
no single “correct” answer to be discovered. The advan-
tage of PRECIS-2 is that it makes these judgments explicit 
and therefore able to be discussed by the trial team.
PRECIS-2 could be a tool in a multifaceted package to 
help trialists design trials that meet the users’ needs. 
For instance, in the US, the NIH Clinical and Transla-
tional Science Awards (CTSA) Consortium does not con-
duct trials but facilitates their conduct and 
implementation, and PRECIS-2 could used as part of 
those activities.19  Trials units and other centres of trial 
expertise could work through the PRECIS-2 wheel with 
investigators to ensure that trial design decisions are 
consistent with the investigators’ intended purpose. 
The tool could also be a way of promoting trials that effi-
ciently assist in the continued development of evidence 
based care.20  It would thus continue to promote and 
re-energise Archie Cochrane’s vision of efficient effec-
tive healthcare by addressing the issue of applicability 
and extrapolating trial results into real life.21
There is a substantial degree of waste in medical 
research (see http://researchwaste.net). Some of this 
waste is due to trials providing results that are irrele-
vant to the healthcare decisions of those for whom the 
trial was intended to help.4-6  We believe PRECIS-2 can 
help to reduce this waste by raising awareness of the 
need to explicitly consider the match between design 
decisions (and the consequences of these) and the use-
fulness of the future results to the intended audience. 
As Dave Sackett has pointed out, the applicability of the 
results of a trial can never be assured,22 because of the 
complexity of patients, health professionals, clinical 
settings, cultures, and healthcare systems. But using 
PRECIS-2 to consider applicability at the design stage 
will make it more likely that the results of a trial are 
more useful to their intended users than they otherwise 
would have been.
As in the original PRECIS tool, the authors welcome 
feedback on PRECIS-2 to continue the quest to design 
trials fit for purpose.
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